Compare Novo Nordisk A/S (NVO) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs US Bancorp — how do they compare? Novo Nordisk A/S trades at $38.11 (market cap $168.73B), while US Bancorp trades at $57.18 (market cap $87.52B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.7%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and US Bancorp for 97 Days on average.
| NVO | USB | |
|---|---|---|
Market Cap | $168.73B | $87.52B |
Volume | 13,531,267 | 9,184,647 |
Sector | Health | Financials |
52-Week High | $63.98 | $65.42 |
52-Week Low | $35.29 | $45.28 |
Typical Hold Time | 116 Days | 97 Days |
Enterprise Value | $183.05B | $117.01B |
Dividend Yield | 4.7% | 3.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, up 1.73% with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat estimates, with Q2 2026 EPS of $0.96 surpassing the $0.82 expectation. The company maintains robust cash flow generation of $119.1B from operations in 2025.
NVO presents compelling value with a 9.71 P/E ratio and 16.8% upside to the $44.67 consensus target. Key risks include FDA regulatory delays for hemophilia drug denecimig and intensifying competition from Eli Lilly in obesity treatments. The bullish analyst consensus (59% buy ratings) supports the growth outlook despite near-term headwinds.
U.S. Bancorp (USB) trades at $56.17, down 1.95% on the day, with a bearish technical outlook despite strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. USB maintains robust profitability with a 27.61% net income margin and attractive valuation metrics including a P/E of 11.21. Recent news highlights dividend increases and positive business momentum in payments and capital markets.
The stock presents a compelling value opportunity with analyst consensus target of $69.94 (24.5% upside), though technical indicators signal near-term caution. Key risks include interest rate sensitivity and regulatory changes, while institutional sentiment remains positive with 51% buy ratings. The upcoming Q3 earnings report will be critical for confirming the positive fundamental trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
